Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment
نویسنده
چکیده
1. van Hensbroek MB, Onyiorah E, Jaffar S et al. A trial of artemether or quinine in childrenwith cerebralmalaria.NEngl JMed1996; 335: 69–75 2. Hien TT, Day NPJ, Phu NH et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76–83 3. Karunajeewa HA, Mueller I, Senn M et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008; 359: 2545–2557 4. Hoffman SL. Artemether in severe malaria—still too many deaths. N Engl J Med 1996; 335: 124–126 5. Brewer TG, Peggins JO, Grate SJ et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 1994; 88: S33–S36
منابع مشابه
Antioxidant Enzymes and Acute Phase Proteins Correlate with Marker of Lipid Peroxide in Adult Nigerian Sickle Cell Disease Patients
Objective(s) Sickle cell disease is a genetic disorder characterized by chronic haemolytic anaemia. Haemoglobin S containing red blood cells may be susceptible to oxidative stress due to imbalance between production of reactive oxygen species and the countering effect of the various antioxidants present in the body. Materials and Methods We evaluated some antioxidant enzymes which include gl...
متن کاملPHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS
The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...
متن کاملHemoglobin And Hematocrit Rise In End-Stage Renal Disease (ESRD) With PDpoetin: Results Of A Phase Ш, Multicenter Clinical Trial
Background and Objective: The anemia of ESRD is a complex disorder, associated with serious complications, which increases patients’ mortality and morbidity. Treatment of this anemia with recombinant human erythropoietin (rh-EPO) is well established. This clinical trial study was conducted within 20 months, from May 2005 to December 2006, in order to evaluate the efficacy of PDpoetin (rh-EPO...
متن کاملMarked improvement in renal function after rectal cancer resection in a case of anti-neutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis
1. Breen CP, Macdougall IC. Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease. Nephrol Dial Transplant 1998; 13: 2949–2952 2. Tomson CRV, Edmunds ME, Chambers K et al. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 1992; 7: 817–821 ...
متن کاملThe role of secondary hyperparathyroidism in anemia of end stage renal disease
Introduction: secondary hyperparathyroidism is listed among the possible reasons for intensifying the anemia and resistance to erythropoietin therapy in hemodialysis patients. Although its exact mechanism is not entirely clarified, but shift of bone marrow cells to adipocytes, bone marrow fibrosis and decreased calciteriol can be the causes. However, the role of secondary hyperparathyroidism in...
متن کاملAntitetanus Toxoid Antibody Titer of Chronic Hemodialysis Patients in Iran
Background: Patients with end stage renal disease have higher incidence of infection dis-eases that is thought to be related to impaired immune system. Objective: To determine the antitetanus IgG antibody level in Iranian hemodialysis patients with end stage renal disease and to find its association with sex, age, blood hemoglobin, serum albumin, dura-tion of dialysis, time of dialysis per week...
متن کامل